In pancreatic ductal adenocarcinoma treated with CXCR2 signaling inhibitors, the migration of MDSCs and the formation of a niche at the metastatic site are significantly suppressed64. The gene discussed is CXCR2; the disease is pancreatic ductal adenocarcinoma.